These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 974036)

  • 1. Chelate mediated transfer of iron from transferrin to desferrioxamine.
    Pollack S; Aisen P; Lasky FD; Vanderhoff G
    Br J Haematol; 1976 Oct; 34(2):231-5. PubMed ID: 974036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Removal of non-transferrin-bound iron from blood with iron overload using a device with immobilized desferrioxamine.
    Ambrus CM; Stadler I; Toumbis CA; Stadler A; Anthone S; Anthone R; DeAlarcon P; Deshpande G; Conway J; Vladutiu AO; Ambrus JL
    J Med; 1999; 30(3-4):211-24. PubMed ID: 17312675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of chelating agents on iron mobilization in Chang cell cultures.
    White GP; Jacobs A; Grady RW; Cerami A
    Blood; 1976 Dec; 48(6):923-9. PubMed ID: 1000084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron uptake by Chang cells from transferrin, nitriloacetate and citrate complexes: the effects of iron-loading and chelation with desferrioxamine.
    White GP; Jacobs A
    Biochim Biophys Acta; 1978 Oct; 543(2):217-25. PubMed ID: 728460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chelation of transferrin iron by desferrioxamine in K562 cells. The partition of iron between ferrioxamine and ferritin.
    Roberts S; Bomford A
    Biochem J; 1988 Sep; 254(3):869-75. PubMed ID: 3196300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A reappraisal of the effects of iron and desferrioxamine on the growth of Plasmodium falciparum 'in vitro': the unimportance of serum iron.
    Peto TE; Thompson JL
    Br J Haematol; 1986 Jun; 63(2):273-80. PubMed ID: 3521714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy.
    Breuer W; Ermers MJ; Pootrakul P; Abramov A; Hershko C; Cabantchik ZI
    Transfus Sci; 2000 Dec; 23(3):241-2. PubMed ID: 11099901
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical usefulness of iron chelating agents.
    Waxman HS; Brown EB
    Prog Hematol; 1969; 6():338-73. PubMed ID: 4976246
    [No Abstract]   [Full Text] [Related]  

  • 9. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Hydroxypyridine-N-oxides: effective new chelators in iron mobilisation.
    Kontoghiorghes GJ
    Biochim Biophys Acta; 1987 Apr; 924(1):13-8. PubMed ID: 3828392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nontransferrin-bound serum iron in thalassemia and sickle cell patients.
    Ahmed NK; Hanna M; Wang W
    Int J Biochem; 1986; 18(10):953-6. PubMed ID: 3792614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
    Liu J; Obando D; Schipanski LG; Groebler LK; Witting PK; Kalinowski DS; Richardson DR; Codd R
    J Med Chem; 2010 Feb; 53(3):1370-82. PubMed ID: 20041672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients.
    Breuer W; Ghoti H; Shattat A; Goldfarb A; Koren A; Levin C; Rachmilewitz E; Cabantchik ZI
    Am J Hematol; 2012 Jan; 87(1):55-61. PubMed ID: 22125177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
    Devanur LD; Evans RW; Evans PJ; Hider RC
    Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects.
    Summers MR; Jacobs A; Tudway D; Perera P; Ricketts C
    Br J Haematol; 1979 Aug; 42(4):547-55. PubMed ID: 476006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy.
    Grootveld M; Bell JD; Halliwell B; Aruoma OI; Bomford A; Sadler PJ
    J Biol Chem; 1989 Mar; 264(8):4417-22. PubMed ID: 2466835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved oxygen delivery to tissues and iron chelator transport through the use of lysed and resealed red blood cells: a new perspective on Cooley's anemia therapy.
    Ropars C; Teisseire B; Avenard G; Chassaigne M; Hurel C; Girot R; Nicolau C
    Ann N Y Acad Sci; 1985; 445():304-15. PubMed ID: 3860134
    [No Abstract]   [Full Text] [Related]  

  • 18. Iron removal from transferrin. An experimental study.
    Pollack S; Vanderhoff G; Lasky F
    Biochim Biophys Acta; 1977 Apr; 497(2):481-7. PubMed ID: 870073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of desferrioxamine, rhodotorulic acid and cholylhydroxamic acid on transferrin and iron exchange with hepatocytes in culture.
    Baker E; Page M; Torrance J; Grady R
    Clin Physiol Biochem; 1985; 3(6):277-88. PubMed ID: 4075694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant primary hemochromatosis and beta-thalassemia trait: iron depletion by erythrocytapheresis and desferrioxamine.
    Cesana M; Mandelli C; Tiribelli C; Bianchi PA; Conte D
    Am J Gastroenterol; 1989 Feb; 84(2):150-2. PubMed ID: 2916524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.